<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Akinetopsia - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .header-dates {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-top: 16px;
            padding-top: 12px;
            border-top: 1px solid rgba(255,255,255,0.22);
            position: relative;
        }

        .date-chip {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            background: rgba(255,255,255,0.14);
            border: 1px solid rgba(255,255,255,0.25);
            border-radius: 999px;
            padding: 5px 10px;
            font-size: 0.82rem;
        }

        .date-chip-label {
            font-weight: 600;
            opacity: 0.95;
        }

        .date-chip time {
            font-variant-numeric: tabular-nums;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Akinetopsia</span>
        </nav>

        <header class="page-header">
            <h1>Akinetopsia</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0000660" target="_blank">
                        MONDO:0000660
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">agnosia</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">mental disorder</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Akinetopsia (motion blindness) is a rare visual cortical disorder characterized by impaired perception of visual motion, with moving objects perceived as disjointed jumps or freeze-frames. The condition is linked to dysfunction of motion-processing regions in the visual cortex, especially area V5/MT.
            </p>
            
            
            <div class="header-dates">
                
                <span class="date-chip">
                    <span class="date-chip-label">Entry created</span>
                    <time datetime="2026-02-02T17:31:18Z">2026-02-02</time>
                </span>
                
                
                <span class="date-chip">
                    <span class="date-chip-label">Last updated</span>
                    <time datetime="2026-02-03T03:24:32Z">2026-02-03</time>
                </span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">10</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Genes</div>
            </div>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#differentials">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Differentials</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">◆</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Cinematographic vision
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Akinetopsia subtype characterized by perceiving motion as a series of discrete frames (cinematographic vision).</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31036340" target="_blank">PMID:31036340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects."</div>
                
                
                <div class="evidence-explanation">This report describes cinematographic vision as one of two reported akinetopsia subtypes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Invisibility of moving objects
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Akinetopsia subtype characterized by failure to perceive moving objects.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31036340" target="_blank">PMID:31036340</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects."</div>
                
                
                <div class="evidence-explanation">This report describes invisibility of moving objects as the second akinetopsia subtype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">10</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">V5/MT motion-processing cortex dysfunction</div>
                
                <div class="item-desc">The disorder reflects disruption of cortical area V5/MT, a key node for visual motion perception, leading to failure of normal motion integration.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000411" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Despite its profound impact, the condition remains poorly understood beyond the established centrality of cortical area V5/MT in visual motion perception."</div>
                
                
                <div class="evidence-explanation">This systematic review highlights V5/MT as central to motion perception, supporting V5/MT dysfunction as a core mechanism.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27193360" target="_blank">PMID:27193360</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"akinetopsia (cortical syndrome in which patient losses the ability to perceive visual motion)"</div>
                
                
                <div class="evidence-explanation">This review defines akinetopsia as a cortical syndrome with loss of visual motion perception.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37938052" target="_blank">PMID:37938052</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Our results revealed distinct characteristics for the various etiologies of this phenomenon in addition to a shared pathophysiologic pathway among them."</div>
                
                
                <div class="evidence-explanation">This systematic review supports a shared pathophysiologic pathway across akinetopsia etiologies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Left V5/MT susceptibility to acute interference</div>
                
                <div class="item-desc">In right-handed individuals, left V5/MT appears particularly susceptible to acute interference during experimental disruption, implicating hemispheric vulnerability in motion perception.</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pathophysiologically, in right-handed individuals, the left area V5/MT was found to be particularly susceptible to acute interference, as evidenced by the experimental studies."</div>
                
                
                <div class="evidence-explanation">This indicates left V5/MT vulnerability to acute interference in experimental cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Right-hemispheric V5/MT predominance in clinical cases</div>
                
                <div class="item-desc">Clinical cases more often involve right-hemispheric V5/MT afflictions, suggesting dominance of the right V5/MT in motion perception.</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"we found a greater prevalence of right-hemispheric afflictions in clinical cases, suggesting that the right area V5/MT plays a more dominant role in motion perception."</div>
                
                
                <div class="evidence-explanation">This supports right-hemisphere predominance for motion perception in clinical akinetopsia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Severity depends on surviving motion network components and stimulus speed</div>
                
                <div class="item-desc">The severity of motion blindness depends on remaining components of the visual motion network and the speed of moving objects.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000411" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the severity of the condition also depends on surviving components of the visual motion network as a whole, and-in line with the dynamic parallellism theory-the speed of moving objects."</div>
                
                
                <div class="evidence-explanation">This supports network redundancy and stimulus speed as modifiers of symptom severity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Structural neurological damage to motion network</div>
                
                <div class="item-desc">Structural neurological conditions such as stroke or neurodegenerative disease most often underlie akinetopsia by damaging cortical motion processing regions.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000411" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Aetiologically, most cases were associated with structural neurological conditions such as stroke and neurodegenerative disease, and fewer with intoxications or paroxysmal neurological disorders such as epilepsy."</div>
                
                
                <div class="evidence-explanation">This supports structural neurological disease as the dominant mechanism leading to motion network damage.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Paroxysmal or intoxication-related cortical dysfunction</div>
                
                <div class="item-desc">A subset of cases arise from transient cortical dysfunction due to intoxications or paroxysmal neurological disorders such as epilepsy.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000411" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Aetiologically, most cases were associated with structural neurological conditions such as stroke and neurodegenerative disease, and fewer with intoxications or paroxysmal neurological disorders such as epilepsy."</div>
                
                
                <div class="evidence-explanation">This indicates that intoxications and paroxysmal disorders can underlie akinetopsia in some cases.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25667833" target="_blank">PMID:25667833</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We describe a patient who showed akinetopsia recurrently as epileptic seizures."</div>
                
                
                <div class="evidence-explanation">This case report documents epileptic seizures presenting as recurrent akinetopsia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Epileptic hyperexcitability of MT/V5 cortex</div>
                
                <div class="item-desc">Paroxysmal hyperexcitability in right temporal and parietal cortices, including MT/V5, can trigger akinetopsia episodes.</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25667833" target="_blank">PMID:25667833</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We diagnosed his visual symptom as akinetopsia, which was aroused by hyperexcitability of the right temporal and parietal cortices, including area MT/V5."</div>
                
                
                <div class="evidence-explanation">This case report attributes akinetopsia to hyperexcitability in right temporal/parietal cortices including MT/V5.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Induced disruption from TMS or medications</div>
                
                <div class="item-desc">Akinetopsia can be induced by transcranial magnetic stimulation or certain medications, implying reversible disruption of motion-processing circuits.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000540" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000411" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40605075" target="_blank">PMID:40605075</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recent cases have demonstrated that it is not necessarily attributed only to vascular causes and neurodegenerative diseases but can also be induced through transcranial magnetic stimulation, and certain medications."</div>
                
                
                <div class="evidence-explanation">This review documents TMS- and medication-induced akinetopsia, supporting reversible circuit disruption mechanisms.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Bilateral V5/MT lesions</div>
                
                <div class="item-desc">Bilateral injury to V5/MT within the secondary visual cortex disrupts motion-processing circuitry.</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bilateral lesions to V5/MT most often coincided with global akinetopsia and chronicity."</div>
                
                
                <div class="evidence-explanation">This links bilateral V5/MT lesions to downstream global and chronic akinetopsia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Global akinetopsia with chronic course</div>
                
                <div class="item-desc">Global motion blindness with chronicity most often occurs when V5/MT is affected bilaterally.</div>
                
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        secondary visual cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0022232" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Bilateral lesions to V5/MT most often coincided with global akinetopsia and chronicity."</div>
                
                
                <div class="evidence-explanation">This supports global and chronic akinetopsia as a frequent outcome of bilateral V5/MT lesions.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">2</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Eye<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Nervous System<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Eye
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hemiakinetopsia
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001123" target="_blank">
                                Visual field defect
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001123)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Of the clinical cases, 12% showed hemiakinetopsia, 50% continuous or progressive symptoms, and 52% a chronic course."</div>
                
                
                <div class="evidence-explanation">This review quantifies hemiakinetopsia among clinical cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Visual motion blindness with freeze-frame perception
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0030222" target="_blank">
                                Visual agnosia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0030222)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Akinetopsia, or visual motion blindness, is a perceptual distortion characteristic of Alice in Wonderland syndrome in which people see moving objects as disjointed &#39;jumps&#39; or &#39;freeze frames.&#39;"</div>
                
                
                <div class="evidence-explanation">This description of motion blindness with freeze-frame perception supports the core phenotype.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Treat underlying condition
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000001" target="_blank">
                            MAXO:0000001
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Treatment is most effective when directed at the underlying cause, while cases due to organic lesions may be therapy-resistant.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Treatments were mostly successful when they were aimed at the underlying condition, while cases due to organic lesions tended to be therapy-resistant."</div>
                
                
                <div class="evidence-explanation">This review indicates treatment success when targeting the underlying condition and resistance in organic lesions.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Carbamazepine for seizure-related akinetopsia
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Antiepileptic therapy can suppress akinetopsia when episodes are driven by epileptic hyperexcitability.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25667833" target="_blank">PMID:25667833</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We administered carbamazepine 200 mg/day, which suppressed his akinetopsic symptom completely."</div>
                
                
                <div class="evidence-explanation">This case report shows carbamazepine suppressed seizure-related akinetopsia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Structural neurological lesions</div>
                
                
                <div class="item-desc">Structural brain conditions such as stroke and neurodegenerative disease are common etiologic contexts for akinetopsia.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Aetiologically, most cases were associated with structural neurological conditions such as stroke and neurodegenerative disease, and fewer with intoxications or paroxysmal neurological disorders such as epilepsy."</div>
                
                
                <div class="evidence-explanation">The review reports structural neurological conditions as the dominant etiologic context.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Intoxications or paroxysmal neurological disorders</div>
                
                
                <div class="item-desc">Some cases are associated with intoxications or paroxysmal disorders such as epilepsy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39996018" target="_blank">PMID:39996018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Aetiologically, most cases were associated with structural neurological conditions such as stroke and neurodegenerative disease, and fewer with intoxications or paroxysmal neurological disorders such as epilepsy."</div>
                
                
                <div class="evidence-explanation">This supports intoxications and paroxysmal disorders as less common etiologies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Transcranial magnetic stimulation exposure</div>
                
                
                <div class="item-desc">Akinetopsia has been reported after transcranial magnetic stimulation, indicating that direct disruption of cortical motion networks can induce symptoms.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40605075" target="_blank">PMID:40605075</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recent cases have demonstrated that it is not necessarily attributed only to vascular causes and neurodegenerative diseases but can also be induced through transcranial magnetic stimulation, and certain medications."</div>
                
                
                <div class="evidence-explanation">This review notes TMS-associated induction of akinetopsia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Medication-induced motion blindness</div>
                
                
                <div class="item-desc">Certain medications can induce akinetopsia, implying reversible pharmacologic disruption of motion processing.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40605075" target="_blank">PMID:40605075</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Recent cases have demonstrated that it is not necessarily attributed only to vascular causes and neurodegenerative diseases but can also be induced through transcranial magnetic stimulation, and certain medications."</div>
                
                
                <div class="evidence-explanation">This review cites medication-induced akinetopsia in recent cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        
        <div class="card" id="differentials">
            <div class="card-header">
                <div class="card-icon" style="background: #fef2f2; color: #dc2626;">🔀</div>
                <h2 class="card-title">Differential Diagnoses</h2>
                <span class="card-count">3</span>
            </div>
            <p style="margin-bottom: 16px; font-size: 0.95rem; color: var(--text-muted);">
                Conditions with similar clinical presentations that must be differentiated from Akinetopsia:
            </p>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Parkinson&#39;s disease
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005180" target="_blank">
                            MONDO:0005180
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Parkinson&#39;s disease can present with visual illusions including akinetopsia, and should be considered when evaluating motion blindness.
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34617361" target="_blank">PMID:34617361</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Other observed illusions included textural illusions, macropsia, micropsia, teleopsia, pelopsia, kinetopsia, akinetopsia, Zeitraffer/Zeitlupen phenomena, tilt illusion, upside-down illusion, and palinopsia."</div>
                
                
                <div class="evidence-explanation">This PD survey reports akinetopsia among visual illusion types, supporting PD as a differential context.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Posterior cortical atrophy
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0018899" target="_blank">
                            MONDO:0018899
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Posterior cortical atrophy (visual-variant Alzheimer&#39;s disease) can present with higher visual processing deficits including akinetopsia.
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38357623" target="_blank">PMID:38357623</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"She also presented with multiple previously unrecognised symptoms indicative of higher visual processing dysfunction, such as alexia without agraphia, ocular motor apraxia, optic ataxia, prosopagnosia, akinetopsia and topographagnosia, so further assessment to investigate for PCA was carried out."</div>
                
                
                <div class="evidence-explanation">This case report links akinetopsia to posterior cortical atrophy as part of the clinical presentation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Occipital or occipito-parietal infarction (stroke)
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005098" target="_blank">
                            MONDO:0005098
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Occipital or occipito-parietal infarction can present with visual disorders including akinetopsia and should be considered in the differential.
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23206528" target="_blank">PMID:23206528</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Visual disorders, such as achromatopsia, akinetopsia or prosopagnosia, were rarely reported by the patients."</div>
                
                
                <div class="evidence-explanation">This infarction cohort reports akinetopsia among visual disorders after occipital/occipito-parietal infarction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Akinetopsia
creation_date: &#39;2026-02-02T17:31:18Z&#39;
updated_date: &#39;2026-02-03T03:24:32Z&#39;
category: Complex
description: &gt;-
  Akinetopsia (motion blindness) is a rare visual cortical disorder characterized
  by impaired perception of visual motion, with moving objects perceived as
  disjointed jumps or freeze-frames. The condition is linked to dysfunction of
  motion-processing regions in the visual cortex, especially area V5/MT.
disease_term:
  preferred_term: akinetopsia
  term:
    id: MONDO:0000660
    label: akinetopsia
parents:
- agnosia
- mental disorder
synonyms:
- Motion blindness
- Visual motion blindness
notes: &gt;-
  Akinetopsia is described as a cortical syndrome in which patients lose the
  ability to perceive visual motion.
prevalence:
- population: Reported cases
  notes: &gt;-
    Since first description in 1911, only a handful of cases have been studied,
    indicating an extremely rare disorder.
  evidence:
  - reference: PMID:40605075
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Since akinetopsia was first described in 1911, only a handful of cases have been studied.&#34;
    explanation: This review emphasizes the rarity of akinetopsia and the limited number of documented cases.
  - reference: PMID:37938052
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Selective motion blindness, also known as akinetopsia, is infrequently reported in the literature.&#34;
    explanation: This systematic review notes that akinetopsia is infrequently reported, supporting rarity.
pathophysiology:
- name: V5/MT motion-processing cortex dysfunction
  description: &gt;-
    The disorder reflects disruption of cortical area V5/MT, a key node for
    visual motion perception, leading to failure of normal motion integration.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: visual cortex
    term:
      id: UBERON:0000411
      label: visual cortex
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Despite its profound impact, the condition remains poorly understood beyond the established centrality of cortical area V5/MT in visual motion perception.&#34;
    explanation: This systematic review highlights V5/MT as central to motion perception, supporting V5/MT dysfunction as a core mechanism.
  - reference: PMID:27193360
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;akinetopsia (cortical syndrome in which patient losses the ability to perceive visual motion)&#34;
    explanation: This review defines akinetopsia as a cortical syndrome with loss of visual motion perception.
  - reference: PMID:37938052
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Our results revealed distinct characteristics for the various etiologies of this phenomenon in addition to a shared pathophysiologic pathway among them.&#34;
    explanation: This systematic review supports a shared pathophysiologic pathway across akinetopsia etiologies.
- name: Left V5/MT susceptibility to acute interference
  description: &gt;-
    In right-handed individuals, left V5/MT appears particularly susceptible
    to acute interference during experimental disruption, implicating
    hemispheric vulnerability in motion perception.
  locations:
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Pathophysiologically, in right-handed individuals, the left area V5/MT was found to be particularly susceptible to acute interference, as evidenced by the experimental studies.&#34;
    explanation: This indicates left V5/MT vulnerability to acute interference in experimental cases.
- name: Right-hemispheric V5/MT predominance in clinical cases
  description: &gt;-
    Clinical cases more often involve right-hemispheric V5/MT afflictions,
    suggesting dominance of the right V5/MT in motion perception.
  locations:
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;we found a greater prevalence of right-hemispheric afflictions in clinical cases, suggesting that the right area V5/MT plays a more dominant role in motion perception.&#34;
    explanation: This supports right-hemisphere predominance for motion perception in clinical akinetopsia.
- name: Severity depends on surviving motion network components and stimulus speed
  description: &gt;-
    The severity of motion blindness depends on remaining components of the
    visual motion network and the speed of moving objects.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: visual cortex
    term:
      id: UBERON:0000411
      label: visual cortex
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;the severity of the condition also depends on surviving components of the visual motion network as a whole, and-in line with the dynamic parallellism theory-the speed of moving objects.&#34;
    explanation: This supports network redundancy and stimulus speed as modifiers of symptom severity.
- name: Structural neurological damage to motion network
  description: &gt;-
    Structural neurological conditions such as stroke or neurodegenerative
    disease most often underlie akinetopsia by damaging cortical motion
    processing regions.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: visual cortex
    term:
      id: UBERON:0000411
      label: visual cortex
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Aetiologically, most cases were associated with structural neurological conditions such as stroke and neurodegenerative disease, and fewer with intoxications or paroxysmal neurological disorders such as epilepsy.&#34;
    explanation: This supports structural neurological disease as the dominant mechanism leading to motion network damage.
- name: Paroxysmal or intoxication-related cortical dysfunction
  description: &gt;-
    A subset of cases arise from transient cortical dysfunction due to
    intoxications or paroxysmal neurological disorders such as epilepsy.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: visual cortex
    term:
      id: UBERON:0000411
      label: visual cortex
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Aetiologically, most cases were associated with structural neurological conditions such as stroke and neurodegenerative disease, and fewer with intoxications or paroxysmal neurological disorders such as epilepsy.&#34;
    explanation: This indicates that intoxications and paroxysmal disorders can underlie akinetopsia in some cases.
  - reference: PMID:25667833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We describe a patient who showed akinetopsia recurrently as epileptic seizures.&#34;
    explanation: This case report documents epileptic seizures presenting as recurrent akinetopsia.
- name: Epileptic hyperexcitability of MT/V5 cortex
  description: &gt;-
    Paroxysmal hyperexcitability in right temporal and parietal cortices,
    including MT/V5, can trigger akinetopsia episodes.
  locations:
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:25667833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We diagnosed his visual symptom as akinetopsia, which was aroused by hyperexcitability of the right temporal and parietal cortices, including area MT/V5.&#34;
    explanation: This case report attributes akinetopsia to hyperexcitability in right temporal/parietal cortices including MT/V5.
- name: Induced disruption from TMS or medications
  description: &gt;-
    Akinetopsia can be induced by transcranial magnetic stimulation or certain
    medications, implying reversible disruption of motion-processing circuits.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  locations:
  - preferred_term: visual cortex
    term:
      id: UBERON:0000411
      label: visual cortex
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:40605075
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Recent cases have demonstrated that it is not necessarily attributed only to vascular causes and neurodegenerative diseases but can also be induced through transcranial magnetic stimulation, and certain medications.&#34;
    explanation: This review documents TMS- and medication-induced akinetopsia, supporting reversible circuit disruption mechanisms.
- name: Bilateral V5/MT lesions
  description: &gt;-
    Bilateral injury to V5/MT within the secondary visual cortex disrupts
    motion-processing circuitry.
  locations:
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Bilateral lesions to V5/MT most often coincided with global akinetopsia and chronicity.&#34;
    explanation: This links bilateral V5/MT lesions to downstream global and chronic akinetopsia.
- name: Global akinetopsia with chronic course
  description: &gt;-
    Global motion blindness with chronicity most often occurs when V5/MT is
    affected bilaterally.
  locations:
  - preferred_term: secondary visual cortex
    term:
      id: UBERON:0022232
      label: secondary visual cortex
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Bilateral lesions to V5/MT most often coincided with global akinetopsia and chronicity.&#34;
    explanation: This supports global and chronic akinetopsia as a frequent outcome of bilateral V5/MT lesions.
phenotypes:
- category: Visual
  name: Visual motion blindness with freeze-frame perception
  description: &gt;-
    Moving objects are perceived as disjointed jumps or freeze frames rather than
    smooth continuous motion.
  phenotype_term:
    preferred_term: Visual agnosia
    term:
      id: HP:0030222
      label: Visual agnosia
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Akinetopsia, or visual motion blindness, is a perceptual distortion characteristic of Alice in Wonderland syndrome in which people see moving objects as disjointed &#39;jumps&#39; or &#39;freeze frames.&#39;&#34;
    explanation: This description of motion blindness with freeze-frame perception supports the core phenotype.
- category: Visual
  name: Hemiakinetopsia
  description: &gt;-
    Motion blindness restricted to one hemifield of vision in a subset of
    clinical cases.
  phenotype_term:
    preferred_term: Visual field defect
    term:
      id: HP:0001123
      label: Visual field defect
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Of the clinical cases, 12% showed hemiakinetopsia, 50% continuous or progressive symptoms, and 52% a chronic course.&#34;
    explanation: This review quantifies hemiakinetopsia among clinical cases.
environmental:
- name: Structural neurological lesions
  description: &gt;-
    Structural brain conditions such as stroke and neurodegenerative disease are
    common etiologic contexts for akinetopsia.
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Aetiologically, most cases were associated with structural neurological conditions such as stroke and neurodegenerative disease, and fewer with intoxications or paroxysmal neurological disorders such as epilepsy.&#34;
    explanation: The review reports structural neurological conditions as the dominant etiologic context.
- name: Intoxications or paroxysmal neurological disorders
  description: &gt;-
    Some cases are associated with intoxications or paroxysmal disorders such as
    epilepsy.
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Aetiologically, most cases were associated with structural neurological conditions such as stroke and neurodegenerative disease, and fewer with intoxications or paroxysmal neurological disorders such as epilepsy.&#34;
    explanation: This supports intoxications and paroxysmal disorders as less common etiologies.
- name: Transcranial magnetic stimulation exposure
  description: &gt;-
    Akinetopsia has been reported after transcranial magnetic stimulation,
    indicating that direct disruption of cortical motion networks can induce
    symptoms.
  evidence:
  - reference: PMID:40605075
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Recent cases have demonstrated that it is not necessarily attributed only to vascular causes and neurodegenerative diseases but can also be induced through transcranial magnetic stimulation, and certain medications.&#34;
    explanation: This review notes TMS-associated induction of akinetopsia.
- name: Medication-induced motion blindness
  description: &gt;-
    Certain medications can induce akinetopsia, implying reversible
    pharmacologic disruption of motion processing.
  evidence:
  - reference: PMID:40605075
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Recent cases have demonstrated that it is not necessarily attributed only to vascular causes and neurodegenerative diseases but can also be induced through transcranial magnetic stimulation, and certain medications.&#34;
    explanation: This review cites medication-induced akinetopsia in recent cases.
treatments:
- name: Treat underlying condition
  description: &gt;-
    Treatment is most effective when directed at the underlying cause, while
    cases due to organic lesions may be therapy-resistant.
  treatment_term:
    preferred_term: medical action
    term:
      id: MAXO:0000001
      label: medical action
  evidence:
  - reference: PMID:39996018
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Treatments were mostly successful when they were aimed at the underlying condition, while cases due to organic lesions tended to be therapy-resistant.&#34;
    explanation: This review indicates treatment success when targeting the underlying condition and resistance in organic lesions.
- name: Carbamazepine for seizure-related akinetopsia
  description: &gt;-
    Antiepileptic therapy can suppress akinetopsia when episodes are driven by
    epileptic hyperexcitability.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: carbamazepine
      term:
        id: CHEBI:3387
        label: carbamazepine
  evidence:
  - reference: PMID:25667833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;We administered carbamazepine 200 mg/day, which suppressed his akinetopsic symptom completely.&#34;
    explanation: This case report shows carbamazepine suppressed seizure-related akinetopsia.
has_subtypes:
- name: Cinematographic vision
  description: &gt;-
    Akinetopsia subtype characterized by perceiving motion as a series of
    discrete frames (cinematographic vision).
  evidence:
  - reference: PMID:31036340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects.&#34;
    explanation: This report describes cinematographic vision as one of two reported akinetopsia subtypes.
- name: Invisibility of moving objects
  description: &gt;-
    Akinetopsia subtype characterized by failure to perceive moving objects.
  evidence:
  - reference: PMID:31036340
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects.&#34;
    explanation: This report describes invisibility of moving objects as the second akinetopsia subtype.
differential_diagnoses:
- name: Parkinson&#39;s disease
  description: &gt;-
    Parkinson&#39;s disease can present with visual illusions including
    akinetopsia, and should be considered when evaluating motion blindness.
  disease_term:
    preferred_term: Parkinson disease
    term:
      id: MONDO:0005180
      label: Parkinson disease
  evidence:
  - reference: PMID:34617361
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Other observed illusions included textural illusions, macropsia, micropsia, teleopsia, pelopsia, kinetopsia, akinetopsia, Zeitraffer/Zeitlupen phenomena, tilt illusion, upside-down illusion, and palinopsia.&#34;
    explanation: This PD survey reports akinetopsia among visual illusion types, supporting PD as a differential context.
- name: Posterior cortical atrophy
  description: &gt;-
    Posterior cortical atrophy (visual-variant Alzheimer&#39;s disease) can present
    with higher visual processing deficits including akinetopsia.
  disease_term:
    preferred_term: posterior cortical atrophy
    term:
      id: MONDO:0018899
      label: posterior cortical atrophy
  evidence:
  - reference: PMID:38357623
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;She also presented with multiple previously unrecognised symptoms indicative of higher visual processing dysfunction, such as alexia without agraphia, ocular motor apraxia, optic ataxia, prosopagnosia, akinetopsia and topographagnosia, so further assessment to investigate for PCA was carried out.&#34;
    explanation: This case report links akinetopsia to posterior cortical atrophy as part of the clinical presentation.
- name: Occipital or occipito-parietal infarction (stroke)
  description: &gt;-
    Occipital or occipito-parietal infarction can present with visual disorders
    including akinetopsia and should be considered in the differential.
  disease_term:
    preferred_term: stroke disorder
    term:
      id: MONDO:0005098
      label: stroke disorder
  evidence:
  - reference: PMID:23206528
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Visual disorders, such as achromatopsia, akinetopsia or prosopagnosia, were rarely reported by the patients.&#34;
    explanation: This infarction cohort reports akinetopsia among visual disorders after occipital/occipito-parietal infarction.
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Akinetopsia.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>